Catriona Jamieson
University of California, San Diego · University of California Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Catriona Jamieson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:26 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02860676 · Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961University of California, San Diego · completed · Chronic Lymphocytic Leukemia · principal investigator
- Ph1NCT02222688 · UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic LeukemiaThomas Kipps · completed · Chronic Lymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Exploring the Impact of Base Deaminase Deregulation on Precancer EvolutionR01CA296974 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2025 to 2026 · $445,092 awarded in 2026Same name and institution; not confirmed by an ID
- Characterization of the Role of ADAR1 in Oncogenic Transformation of ProgenitorsR01CA205944 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2017 to 2021 · $354,563 awarded in 2021Same name and institution; not confirmed by an ID
- Defining the Niche-dependent Role of RNA Editing in Aged and MDS Hematopoietic Stem and Progenitor Cell DysfunctionR01DK114468 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2017 to 2021 · $355,500 awarded in 2021Same name and institution; not confirmed by an ID
- (PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiating cell maintenanceR21CA194679 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2015 to 2016 · $160,885 awarded in 2016Same name and institution; not confirmed by an ID
- Identifying microRNA Targets for Early Detection of Myeloproliferative NeoplasmsR21CA189705 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2015 to 2016 · $168,563 awarded in 2016Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:26 UTC. The ranking covers the 200 most relevant of 48 PubMed records, and a shared surname and initials can bring in a namesake. All 48 on PubMed
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.JAMA Oncol · 2018355 citationsRCR 11.4
- 339 citationsRCR 7.6
- Neurotransplantation for patients with subcortical motor stroke: a phase 2 randomized trial.J Neurosurg · 2005329 citationsRCR 7.8
- A First-in-Human, Phase I Study of Neural Stem Cell Transplantation for Chronic Spinal Cord Injury.Cell Stem Cell · 2018287 citationsRCR 12.8
- Small doses of subcutaneous sodium heparin in preventing deep venous thrombosis after major surgery.Lancet · 1972238 citationsRCR 13.7
- 199 citationsRCR 8.7
- Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.Cell Stem Cell · 2018177 citationsRCR 5.7
- 134 citationsRCR 3.3
- Randomized, double-blind trial of long-chain polyunsaturated fatty acid supplementation with fish oil and borage oil in preterm infants.J Pediatr · 2004119 citationsRCR 3.9
- Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.J Clin Oncol · 2022118 citationsRCR 7.5